Onsat OSF 4 mg (Oral Soluble Film)

Unit Price: ৳ 12.00 (1 x 10: ৳ 120.00)

Medicine Details

Category	Details
Generic	Ondansetron
Company	Beximco pharmaceuticals ltd
Also available as	Onsat 8 mg tablet Onsat 8 mg injection Onsat osf 8 mg oral soluble film

Onsat OSF is a serotonin subtype 3 (5-HT3) receptor antagonist indicated for the prevention of nausea and vomiting associated with various conditions including emetogenic cancer chemotherapy, post-operative nausea and vomiting, and radiotherapy-induced nausea and vomiting. It is an orally dissolving film designed to be applied on the tongue and does not require water for dissolution or swallowing. The active ingredient is Onsat OSF base, a racemic form of Onsat OSF, which is a selective blocking agent of the serotonin 5-HT3 receptor type.

Adults, Pediatric patients (6 months to 18 years) can take 8 mg or 4 mg orodispersible tablet or injections for various conditions such as chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and postoperative nausea and vomiting. Different dosages are recommended based on the specific condition and patient age/weight.

Ondansetron, the active ingredient, is a potent, highly selective 5HT3 receptor-antagonist. Its precise mode of action in the control of nausea and vomiting is not known. It is believed to block the initiation of vomiting reflex triggered by chemotherapeutic agents and radiotherapy by antagonizing 5HT3 receptors on neurons located in the peripheral and central nervous systems.

Oral soluble film should be torn from the pouch and placed on the tongue, where it dissolves within 20 seconds and is then swallowed with saliva. It should not be chewed or swallowed whole, and hands should be washed after taking the film.

Onsat OSF does not induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. However, inducers or inhibitors of these enzymes may change the clearance and half-life of Onsat OSF.

Contraindicated in patients known to have hypersensitivity to the drug or its components, as well as those undergoing concomitant use of apomorphine.

Common adverse events include headache, constipation, diarrhea, and rash. Other reported side effects include sensations of flushing or warmth, hiccups, liver enzyme abnormalities, anaphylaxis, bronchospasm, tachycardia, angina, hypokalemia, and shortness of breath. Rates of these events were not significantly different from placebo in select cases.

Carcinogenic effects were not observed in animal studies, and the drug was not mutagenic. While reproduction studies in pregnant animals showed no evidence of harm to the fetus, caution should be exercised when administering to nursing women.

Hypersensitivity reactions have been reported in patients with hypersensitivity to other selective 5-HT3 receptor antagonists. Onsat OSF does not stimulate gastric or intestinal peristalsis and should not be used instead of nasogastric suction. It may mask a progressive ileus and/or gastric distension in certain patients.

Dosage recommendations are similar for patients with impaired renal function and those over 65 years of age. In those with severe hepatic impairment, a single maximal daily dose of 8 mg is recommended. Limited information is available about dosage in pediatric patients aged 4 years or younger.

Store at a temperature not exceeding 30°C in a dry place, protected from light and moisture.